{
    "clinical_study": {
        "@rank": "104396", 
        "arm_group": [
            {
                "arm_group_label": "Insulin 287 + placebo", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will receive one of two treatment combinations: either insulin 287 + placebo or insulin degludec + placebo. Dose escalation design (4 dose levels)."
            }, 
            {
                "arm_group_label": "Insulin degludec + placebo", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects will receive one of two treatment combinations: either insulin 287 + placebo or insulin degludec + placebo. Dose escalation design (4 dose levels)."
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in Europe. The aim of the trial is to investigate the safety,\n      tolerability, pharmacokinetics (the exposure of the trial drug in the body) and\n      pharmacodynamics (the effect of the investigated drug on the body) of subcutaneously\n      administered NNC0148-0287 (insulin 287) in subjects with type 2 diabetes"
        }, 
        "brief_title": "A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered NNC0148-0287 (Insulin 287) in Subjects With Type 2 Diabetes", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Diabetes", 
            "Type 2 Diabetes Mellitus"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female, age between 18 and 64 years (both inclusive) at the time of signing\n             informed consent\n\n          -  Females of no childbearing potential [if surgically sterilized (i.e. tubal ligation,\n             bilateral oophorectomises or hysterectomised) for at least 3 months or if\n             post-menopausal (i.e. as defined by amenorrhoea for at least 12 months prior to\n             screening and documented by FSH (follicle-stimulating hormone) levels above 40 U/L]\n\n          -  Body mass index (BMI) between 20.0 and 35.0 kg/m^2 (both inclusive)\n\n          -  Type 2 diabetes mellitus (as diagnosed clinically) for at least 12 months\n\n        Exclusion Criteria:\n\n          -  Known or suspected hypersensitivity to trial products or related products\n\n          -  Receipt of any investigational medicinal products within 3 months before screening\n\n          -  Use of oral antidiabetic drugs (OADs) or glucagon-like peptide-1 (GLP-1) receptor\n             agonists (exenatide, liraglutide) within 3 months prior to screening"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "64 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 22, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02148861", 
            "org_study_id": "NN1436-4057", 
            "secondary_id": [
                "2013-001180-22", 
                "U1111-1140-5344"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Insulin 287 + placebo", 
                "description": "Administered once-weekly subcutaneously (s.c., under the skin) for 35 days", 
                "intervention_name": "insulin 287", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Insulin degludec + placebo", 
                "description": "Administered once-daily subcutaneously (s.c., under the skin) for 35 days", 
                "intervention_name": "insulin degludec", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Insulin 287 + placebo", 
                "description": "Administered subcutaneously (s.c., under the skin) once-daily for 35 days", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Insulin degludec + placebo", 
                "description": "Administered once-weekly subcutaneously (s.c., under the skin) for 35 days", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Insulin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 28, 2014", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Neuss", 
                    "country": "Germany", 
                    "zip": "41460"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multiple Dose Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered NNC0148-0287 (Insulin 287) in Subjects With Type 2 Diabetes", 
        "overall_contact": {
            "email": "clinicaltrials@novonordisk.com", 
            "last_name": "Novo Nordisk"
        }, 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Global Clinical Registry (GCR, 1452)", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of treatment emergent adverse events", 
            "safety_issue": "No", 
            "time_frame": "From the first trial product administration at Day 1 until completion of the post-treatment follow-up visit (3-14 days after Visit 9, Day 65)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02148861"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Area under the steady-state serum insulin 287 concentration-time curve", 
                "safety_issue": "No", 
                "time_frame": "During one dosing interval at steady-state from 0 to 168 h after last dose (Day 29)"
            }, 
            {
                "measure": "area under the glucose infusion rate - time curve at steady-state", 
                "safety_issue": "No", 
                "time_frame": "At Day 31 and day 35"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}